Whitehawk Therapeutics Inc WHWK
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
-
Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference
-
Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload
-
Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit
-
Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum
-
Whitehawk Therapeutics Announces $87.5M Private Placement Equity Financing
-
Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
-
Whitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026
Trading Information
- Previous Close Price
- $4.10
- Day Range
- $4.04–4.26
- 52-Week Range
- $1.57–5.50
- Bid/Ask
- $4.01 / $4.27
- Shares Outstanding
- 49.45M
- Market Cap
- $206.22M
- Volume/Avg
- 345,872 / 301,293
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 23
- Website
- https://www.whitehawktx.com
Valuation
|
Metric
|
WHWK
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.69 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
WHWK
Financial Strength
|
Metric
|
WHWK
|
|---|---|
Quick Ratio | 11.13 |
Current Ratio | 11.36 |
Interest Coverage | — |
Quick Ratio
WHWK
Profitability
|
Metric
|
WHWK
|
|---|---|
Return on Assets (Normalized) | −61.19% |
Return on Equity (Normalized) | −65.49% |
Return on Invested Capital (Normalized) | −69.71% |
Return on Assets
WHWK
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Znzhxyhpp | Yymnpvd | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Hyygrjfs | Ltgxfr | $64B | |||
| argenx SE ADR
ARGX
| Nvwjxfm | Zckv | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Dbqwxwgv | Zbrty | $38B | |||
| Royalty Pharma PLC Class A
RPRX
| Lqrhqpzf | Nfkqrxl | $24B | |||
| BioNTech SE ADR
BNTX
| Gbsqqkpq | Kgq | $23B | |||
| Incyte Corp
INCY
| Fhdrmywn | Mgkn | $22B | |||
| Moderna Inc
MRNA
| Wkbpkzl | Svl | $20B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Wnpqqdzw | Lwd | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Rnyjlhzq | Gkqv | $13B |
United States